The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
External link for Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) and LUNGevity recently hosted a one-day cancer screening event at MSK's Ralph Lauren Center in Harlem. Members in the community spoke to experts about prevention, cancer screening, and even had the option to receive day-of screening. Swipe to view some images from the event.
The Center for Implementation Research in Cancer in Later Life (CIRCL), a collaboration between Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine is now accepting applications for the annual pilot award program. CIRCL will be awarding two 12-month awards for $40,000 each plus 20% allowable indirect costs. Learn more and apply here: https://bit.ly/49Mo0Br
🚨: A new FDA approval gives hope to people with stomach and esophagus cancer. The clinical trial that resulted the approval, led by Dr. Yelena Janjigian and researchers at Memorial Sloan Kettering Cancer Center (MSK), investigated using the immunotherapy treatment durvalumab (INFINZI) in combination with a standard-of-care chemotherapy regimen before and after surgery. The success of the trial led the FDA to approve the use of the treatment in people with early stage gastric and gastroesophageal cancers, making durvalumab the first and only immunotherapy approved for these patients before and after surgery. Read more: https://bit.ly/3XgCrWX
Receiving a lung cancer diagnosis can come with a wave of feelings. “Many people feel a profound loss of control after learning they have lung cancer,” says Barbara Mitchell, a clinical social worker at Memorial Sloan Kettering Cancer Center (MSK). Swipe for tips on how to discuss lung cancer with loved ones, friends, employers, and others. https://bit.ly/4ipMkey
Members of Memorial Sloan Kettering Cancer Center (MSK)'s Global Cancer Research and Training (GCRT) Program recently joined colleagues from around the world at the 2025 African Organization for Research and Training in Cancer (AORTIC) Conference in Hammamet, Tunisia. The biennial meeting gathered clinicians, researchers, policymakers, and advocates committed to improving cancer care in Africa. This year marked MSK’s seventh consecutive AORTIC participation, which featured expert-led sessions spanning epidemiology, early detection, treatment innovation, and palliative care. A side meeting also convened U.S. cancer centers focused on global oncology, where MSK’s GCRT leadership represented the institution’s long-standing commitment to equitable cancer care worldwide. Dr. T. Peter Kingham, a hepatopancreatobiliary surgeon at MSK who also serves as Director of MSK’s GCRT Program, shares: “Our collaborative group delivered 46 presentations covering a wide range of topics — including diagnosis with a focus on artificial intelligence, treatment, and the evaluation of our training and education programs.” In addition to Dr. Kingham, MSK was represented by a multidisciplinary team whose work continues to strengthen research, training, and clinical collaborations across the region.
Memorial Sloan Kettering Cancer Center reposted this
A heartfelt thank you to Memorial Sloan Kettering Cancer Center for their generous support in helping us serve the Harlem community this holiday season. Through their partnership, we're able to provide much-needed food to our neighbors facing challenges during this difficult time — from the government shutdown and interrupted SNAP assistance to the rising burden of healthcare costs. We are grateful for their ongoing commitment to Catholic Charities of New York’s Kennedy Community Center and for their dedication to making a positive impact in Harlem. Together, we can continue to create stronger, healthier communities! 💙
Applications for the Quantitative Sciences Undergraduate Research Experience (QSURE) 2026 summer internship program at Memorial Sloan Kettering Cancer Center (MSK) are now open! This program provides undergraduate students hands-on skills in biostatistics, epidemiology, health outcomes, and computational oncology. The deadline to apply is 1/19. Learn more: https://bit.ly/4r9OKC5
The FDA has granted full approval to the targeted immunotherapy drug tarlatamab (Imdelltra®) for treating adults with advanced small cell lung cancer (SCLC) that that has spread after platinum-based chemotherapy. The approval was based on an international phase 3 clinical trial led by Dr. Charles Rudin, a scientist and thoracic medical oncologist at Memorial Sloan Kettering Cancer Center (MSK). “This FDA approval confirms that tarlatamab is a better option than traditional chemotherapy for most patients with recurrent small cell lung cancer,” says Dr. Rudin. Learn more: https://bit.ly/4obiqvF
Miss America 2026, Cassie Donegan, recently visited MSK Kids, the pediatric program at Memorial Sloan Kettering Cancer Center (MSK). Cassie spent time with patients and their families and handed out sashes and tiaras. Her visit was part of The Society of MSK's "Miracle on Madison" event, which raises money for MSK's pediatric cancer programs. Swipe for a few images from the event. 👑
In Scientific American's December 2025 cover story, Memorial Sloan Kettering Cancer Center (MSK) researchers including Dr. Vinod Balachandran and Dr. Benjamin Greenbaum, showcase how mRNA-based vaccines can be personalized to target a patient’s unique tumor mutations. This groundbreaking work is part of MSK's Olayan Center for Cancer Vaccines, which is pioneering science and transformative clinical trials to accelerate precision cancer vaccines as the next breakthrough cancer therapy. https://bit.ly/487K4DY